Head of Grants Office at Karolinska Institutet.
I am leading a unit with highly qualified staff that represent a strong mix of capabilities within scientific research and administration, scientific writing, communication and knowledge within the domains of the European Union and other international and national funding bodies.
Working in the borderland of academia and life science industry I have over the years gained a deep knowledge in the various national and European funding programs.
Over the past 15 years, I have work in, and in support of, innovation driven research and its financing. I graduated 1994 in Molecular Pharmacology at the University of Lund followed by postgraduate training 1995-2000 at Karolinska Institutet where I received a doctorate degree in Neuropharmacology. After two years post-doc supported by the Swedish Brain foundation, I joined Biovitrum AB where I worked 2003-2005 with target validation and assay development. In 2005-2012 I worked for Actar AB where main responsibilities included in-licensing evaluation and due diligence of research projects, management and research strategy. Other major duties included project evaluation and planning, infrastructure build-up and recruitment. At SwedenBIO my main tasks was to to help Swedish Life Science SMEs obtain funding from the EU's Framework Program (FP7) for Research and Technological Development, providing information, advice and to identify relevant calls.
Specialties: Drug Discovery and development in the pharmaceutical industry; Target validation and assay development, soft money, funding, grant applications, EU's Framework Program (FP7) and Horizon 2020.
Karolinska Institutet, Ph.D. received 10:th of March 2000 in Pharmacology
University of Lund, Master of Science in Mathematic and Nature science 1989-1993
Grants Office is part of the Researcher Support Office at the Karolinska Institutet university administration. Our personnel represent a strong mix of capabilities within scientific research and administration, scientific writing, communication and knowledge within the domains of the European Union and other international and national funding bodies.
Grants Office supports researchers at Karolinska Institutet with guidance and advice throughout the complete process of finding and applying for external research funding up until final closure of the project.
We focus on funding from European and US sponsors such as the NIH as well as national and Nordic sponsors in larger calls for proposals. Grants Office communicates information from sponsors and identifies future trends in science and intentions of funding organisations.
Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells
Biochemical pharmacology 2001;61(4):443-8
Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum
Molecular pharmacology 2000;58(4):771-7
GTP differentially affects antagonist radioligand binding to adenosine A(1) and A(2A) receptors in human brain
P2Y receptors contribute to ATP-induced increases in intracellular calcium in differentiated but not undifferentiated PC12 cells
Structure and function of adenosine receptors and their genes
Naunyn-Schmiedeberg's archives of pharmacology 2000;362(4-5):364-74
Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors
Biochemical pharmacology 1999;57(1):65-75
Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors
Biochemical pharmacology 1999;58(6):1035-45
Signaling via A2A adenosine receptor in four PC12 cell clones
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(1):28-32
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 1998;357(1):1-9
Locating the neuronal targets for caffeine
DRUG DEVELOPMENT RESEARCH 1998;45(3-4):324-328
Characterization of human A(2A) adenosine receptors with the antagonist radioligand [H-3]-SCH 58261
BRITISH JOURNAL OF PHARMACOLOGY 1997;121(3):353-60
Localization of adenosine receptor messenger RNAs in the rat eye
Experimental eye research 1997;65(5):595-602
Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells
European journal of pharmacology 1996;316(2-3):325-31
Adenosine (P1) receptor signalling
DRUG DEVELOPMENT RESEARCH 1996;39(3-4):262-268
P2x purinoceptor is not important in thymocyte apoptosis
Immunology letters 1996;49(3):197-201